MaxCyte, Inc., a commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialisation, has announced the signing of a strategic platform license (SPL) with Catamaran Bio, Inc.,  a biotechnology company developing novel, off the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat a broad rang...